WO2005084577A1 - Osseoinductive magnesium-titanate implant and method of manufacturing the same - Google Patents
Osseoinductive magnesium-titanate implant and method of manufacturing the same Download PDFInfo
- Publication number
- WO2005084577A1 WO2005084577A1 PCT/KR2004/000460 KR2004000460W WO2005084577A1 WO 2005084577 A1 WO2005084577 A1 WO 2005084577A1 KR 2004000460 W KR2004000460 W KR 2004000460W WO 2005084577 A1 WO2005084577 A1 WO 2005084577A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- oxide film
- implant
- magnesium titanate
- magnesium
- titanate oxide
- Prior art date
Links
- 239000007943 implant Substances 0.000 title claims abstract description 92
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 10
- 239000011777 magnesium Substances 0.000 claims abstract description 137
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims abstract description 134
- 229910052749 magnesium Inorganic materials 0.000 claims abstract description 134
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims abstract description 120
- 230000003647 oxidation Effects 0.000 claims abstract description 25
- 238000007254 oxidation reaction Methods 0.000 claims abstract description 25
- 238000000034 method Methods 0.000 claims abstract description 22
- 239000010936 titanium Substances 0.000 claims abstract description 18
- 229910052719 titanium Inorganic materials 0.000 claims abstract description 17
- 239000008151 electrolyte solution Substances 0.000 claims abstract description 15
- 229910001069 Ti alloy Inorganic materials 0.000 claims abstract description 13
- 239000011248 coating agent Substances 0.000 claims abstract description 7
- 238000000576 coating method Methods 0.000 claims abstract description 7
- 239000012153 distilled water Substances 0.000 claims abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 6
- 238000007598 dipping method Methods 0.000 claims abstract description 4
- 230000001678 irradiating effect Effects 0.000 claims abstract description 4
- 239000011259 mixed solution Substances 0.000 claims description 9
- 230000015556 catabolic process Effects 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 6
- 230000004888 barrier function Effects 0.000 claims description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- 239000002075 main ingredient Substances 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- 238000010883 osseointegration Methods 0.000 abstract description 12
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 abstract description 9
- 230000001965 increasing effect Effects 0.000 abstract description 9
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 abstract description 9
- 238000001356 surgical procedure Methods 0.000 abstract description 8
- 238000002316 cosmetic surgery Methods 0.000 abstract description 4
- 230000000399 orthopedic effect Effects 0.000 abstract description 4
- 238000003780 insertion Methods 0.000 abstract description 2
- 230000037431 insertion Effects 0.000 abstract description 2
- 229940091250 magnesium supplement Drugs 0.000 description 107
- 210000000988 bone and bone Anatomy 0.000 description 19
- 229940021013 electrolyte solution Drugs 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 9
- 239000011148 porous material Substances 0.000 description 9
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 8
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 238000000635 electron micrograph Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 238000004451 qualitative analysis Methods 0.000 description 5
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 5
- -1 CaHPO) Chemical compound 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 4
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229960005069 calcium Drugs 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 239000001506 calcium phosphate Substances 0.000 description 4
- RBLGLDWTCZMLRW-UHFFFAOYSA-K dicalcium;phosphate;dihydrate Chemical compound O.O.[Ca+2].[Ca+2].[O-]P([O-])([O-])=O RBLGLDWTCZMLRW-UHFFFAOYSA-K 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- YIXJRHPUWRPCBB-UHFFFAOYSA-N magnesium nitrate Chemical compound [Mg+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O YIXJRHPUWRPCBB-UHFFFAOYSA-N 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 229910052698 phosphorus Inorganic materials 0.000 description 4
- 239000011574 phosphorus Substances 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 108060003393 Granulin Proteins 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 238000013019 agitation Methods 0.000 description 3
- 210000002805 bone matrix Anatomy 0.000 description 3
- 239000006172 buffering agent Substances 0.000 description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 description 3
- 229960001714 calcium phosphate Drugs 0.000 description 3
- 235000011010 calcium phosphates Nutrition 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 3
- 229910001425 magnesium ion Inorganic materials 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 235000006408 oxalic acid Nutrition 0.000 description 3
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 238000004381 surface treatment Methods 0.000 description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 2
- 239000004327 boric acid Substances 0.000 description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
- 230000032798 delamination Effects 0.000 description 2
- 238000000151 deposition Methods 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000005468 ion implantation Methods 0.000 description 2
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 2
- 239000011654 magnesium acetate Substances 0.000 description 2
- 229940069446 magnesium acetate Drugs 0.000 description 2
- 235000011285 magnesium acetate Nutrition 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 2
- 239000001755 magnesium gluconate Substances 0.000 description 2
- 229960003035 magnesium gluconate Drugs 0.000 description 2
- 235000015778 magnesium gluconate Nutrition 0.000 description 2
- 239000000347 magnesium hydroxide Substances 0.000 description 2
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 2
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 2
- 239000004137 magnesium phosphate Substances 0.000 description 2
- 229960002261 magnesium phosphate Drugs 0.000 description 2
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 2
- 235000010994 magnesium phosphates Nutrition 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- IAKLPCRFBAZVRW-XRDLMGPZSA-L magnesium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;hydrate Chemical compound O.[Mg+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O IAKLPCRFBAZVRW-XRDLMGPZSA-L 0.000 description 2
- UYNRPXVNKVAGAN-UHFFFAOYSA-L magnesium;diiodate Chemical compound [Mg+2].[O-]I(=O)=O.[O-]I(=O)=O UYNRPXVNKVAGAN-UHFFFAOYSA-L 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000003313 weakening effect Effects 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010028750 Integrin-Binding Sialoprotein Proteins 0.000 description 1
- 102000016921 Integrin-Binding Sialoprotein Human genes 0.000 description 1
- 108090000573 Osteocalcin Proteins 0.000 description 1
- 102000004067 Osteocalcin Human genes 0.000 description 1
- 102100026747 Osteomodulin Human genes 0.000 description 1
- 108010077077 Osteonectin Proteins 0.000 description 1
- 102000009890 Osteonectin Human genes 0.000 description 1
- 102000004264 Osteopontin Human genes 0.000 description 1
- 108010081689 Osteopontin Proteins 0.000 description 1
- 108060008245 Thrombospondin Proteins 0.000 description 1
- 102000002938 Thrombospondin Human genes 0.000 description 1
- 108010031318 Vitronectin Proteins 0.000 description 1
- 102100035140 Vitronectin Human genes 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000003462 bioceramic Substances 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 239000005312 bioglass Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 238000005422 blasting Methods 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000005229 chemical vapour deposition Methods 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 238000005530 etching Methods 0.000 description 1
- 108060002895 fibrillin Proteins 0.000 description 1
- 102000013370 fibrillin Human genes 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 108010078960 osteoadherin Proteins 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000005240 physical vapour deposition Methods 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- LFULEKSKNZEWOE-UHFFFAOYSA-N propanil Chemical compound CCC(=O)NC1=CC=C(Cl)C(Cl)=C1 LFULEKSKNZEWOE-UHFFFAOYSA-N 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000007847 structural defect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000005211 surface analysis Methods 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
- C25D—PROCESSES FOR THE ELECTROLYTIC OR ELECTROPHORETIC PRODUCTION OF COATINGS; ELECTROFORMING; APPARATUS THEREFOR
- C25D11/00—Electrolytic coating by surface reaction, i.e. forming conversion layers
- C25D11/02—Anodisation
- C25D11/26—Anodisation of refractory metals or alloys based thereon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61C—DENTISTRY; APPARATUS OR METHODS FOR ORAL OR DENTAL HYGIENE
- A61C8/00—Means to be fixed to the jaw-bone for consolidating natural teeth or for fixing dental prostheses thereon; Dental implants; Implanting tools
- A61C8/0012—Means to be fixed to the jaw-bone for consolidating natural teeth or for fixing dental prostheses thereon; Dental implants; Implanting tools characterised by the material or composition, e.g. ceramics, surface layer, metal alloy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61C—DENTISTRY; APPARATUS OR METHODS FOR ORAL OR DENTAL HYGIENE
- A61C8/00—Means to be fixed to the jaw-bone for consolidating natural teeth or for fixing dental prostheses thereon; Dental implants; Implanting tools
- A61C8/0012—Means to be fixed to the jaw-bone for consolidating natural teeth or for fixing dental prostheses thereon; Dental implants; Implanting tools characterised by the material or composition, e.g. ceramics, surface layer, metal alloy
- A61C8/0013—Means to be fixed to the jaw-bone for consolidating natural teeth or for fixing dental prostheses thereon; Dental implants; Implanting tools characterised by the material or composition, e.g. ceramics, surface layer, metal alloy with a surface layer, coating
- A61C8/0015—Means to be fixed to the jaw-bone for consolidating natural teeth or for fixing dental prostheses thereon; Dental implants; Implanting tools characterised by the material or composition, e.g. ceramics, surface layer, metal alloy with a surface layer, coating being a conversion layer, e.g. oxide layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/30767—Special external or bone-contacting surface, e.g. coating for improving bone ingrowth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/04—Metals or alloys
- A61L27/06—Titanium or titanium alloys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/30—Inorganic materials
- A61L27/306—Other specific inorganic materials not covered by A61L27/303 - A61L27/32
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- C—CHEMISTRY; METALLURGY
- C23—COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; CHEMICAL SURFACE TREATMENT; DIFFUSION TREATMENT OF METALLIC MATERIAL; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL; INHIBITING CORROSION OF METALLIC MATERIAL OR INCRUSTATION IN GENERAL
- C23C—COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; SURFACE TREATMENT OF METALLIC MATERIAL BY DIFFUSION INTO THE SURFACE, BY CHEMICAL CONVERSION OR SUBSTITUTION; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL
- C23C8/00—Solid state diffusion of only non-metal elements into metallic material surfaces; Chemical surface treatment of metallic material by reaction of the surface with a reactive gas, leaving reaction products of surface material in the coating, e.g. conversion coatings, passivation of metals
- C23C8/40—Solid state diffusion of only non-metal elements into metallic material surfaces; Chemical surface treatment of metallic material by reaction of the surface with a reactive gas, leaving reaction products of surface material in the coating, e.g. conversion coatings, passivation of metals using liquids, e.g. salt baths, liquid suspensions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/3094—Designing or manufacturing processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/30—Joints
- A61F2/30767—Special external or bone-contacting surface, e.g. coating for improving bone ingrowth
- A61F2002/30929—Special external or bone-contacting surface, e.g. coating for improving bone ingrowth having at least two superposed coatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
- A61F2310/00005—The prosthesis being constructed from a particular material
- A61F2310/00011—Metals or alloys
- A61F2310/00023—Titanium or titanium-based alloys, e.g. Ti-Ni alloys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
- A61F2310/00389—The prosthesis being coated or covered with a particular material
- A61F2310/00592—Coating or prosthesis-covering structure made of ceramics or of ceramic-like compounds
- A61F2310/00598—Coating or prosthesis-covering structure made of compounds based on metal oxides or hydroxides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/249921—Web or sheet containing structurally defined element or component
- Y10T428/249953—Composite having voids in a component [e.g., porous, cellular, etc.]
Definitions
- the present invention relates to a magnesium titanate oxide film implant for insertion into a living body, utilized in medical fields such as dentistry, orthopedic surgery, maxillofacial surgery and plastic surgery, and a method for preparing the same.
- titanium (or titanium alloy) implants are subjected to a variety of surface treatments to improve biocompatibility thereof following lathe processing and milling.
- surface treatment methods mention may be made of etching in acidic/alkaline solutions, particle blasting, plasma spray, thermal oxidation, sol-gel induced coating using bioactive materials such as hydroxyapatite, bioglass and bioceramics, physical/chemical vapor deposition, Ion Implantation or Plasma Source Ion Implantation, electrochemical anodic oxidation and applied techniques using any combination thereof.
- Patent No. 1999-01973 a method for preparing an oxide film containing calcium and phosphorus
- US Patent No. 5,478,237 a method for preparing an oxide film containing calcium and phosphorus
- US Patent No. 5,478,237 a method involving forming an anodized film, followed by heat treatment
- US Patent No. 5,354,390 a method involving forming calcium-phosphate using anodic oxidation, followed by heat of hydration treatment so as to prepare hydroxyapatite
- DCPA, CaHPO dicalcium phosphate anhydrous
- alpha-TCP tricalcium phosphate
- ACP amorphous calcium phosphate
- DCPD dicalcium phosphate dihydrate
- the present invention has been made in view of the above problems, and it is an object of the present invention to provide a magnesium titanate oxide film implant having increased biocompatibility and bioactivity of a titanium oxide film formed by anodic oxidation, and a process for preparing the same. It is another object of the present invention to provide a magnesium titanate oxide film implant, by forming an oxide film having osseoinductive properties and excellent mechanical strength on surfaces of titanium and titanium alloy implants, which are utilized in dentistry, orthopedic surgery, otorhinolaryngology, maxillofacial surgery and plastic surgery, so as to induce rapid and strong bone binding, thereby leading to successful osseointegration; and a method for preparing the same.
- a magnesium titanate oxide film implant comprising: an implant body containing titanium or a titanium alloy; and a magnesium titanate oxide film formed on the surface of the body.
- the magnesium titanate oxide film is prepared by low voltage dielectric breakdown anodic oxidation.
- the magnesium titanate oxide film contains 6 to 26% of titanium, 51 to 71% of oxygen and 1.8 to 32%) of magnesium, as main ingredients; 6 to 15% of carbon, 0.3 to 6% of phosphorus, 0.3 to 2.1% of sodium and 1 to 2% of nitrogen, as minor ingredients; and, sulfur, calcium and potassium in an amount of less than 1%, as additives.
- a process for preparing a magnesium titanate oxide film implant comprising: irradiating UN light on an implant body made of titanium or a titanium alloy in distilled water for more than 2 hours; dipping the UN light-irradiated implant body in an electrolyte solution containing magnesium; and coating a magnesium titanate oxide film on the dipped implant body by anodic oxidation at a voltage of 60 to 500N.
- the magnesium titanate oxide film implant in accordance with the present invention is composed of an implant body and a magnesium titanate oxide film formed on the surface of the implant body.
- the implant body used in the present invention is made of titanium or a titanium alloy.
- the magnesium titanate oxide film is formed by incorporating magnesium into the oxide film of the implant at low voltage by dielectric breakdown anodic oxidation, and preferably, contains 1.8 to 50% of magnesium, 6 to 26% of titanium and 51 to 71% of oxygen in an atomic ratio, as main ingredients, and optionally, may further contain 6 to 15% of carbon, 0.3 to 6% of phosphorus, 0.3 to 2.1% of sodium, 1 to 2% of nitrogen, and trace amounts of sulfur, calcium and potassium. Additionally, the magnesium titanate oxide film has a bilayer structure including an upper porous layer and a lower barrier oxide layer. The magnesium titanate oxide film preferably has a thickness of 300 nm to 30 ⁇ m, and more preferably 500 nm to 10 ⁇ m.
- the biochemical action mechanism of the magnesium titanate oxide film implant having such a constitution is as follows.
- the magnesium titanate oxide film implant further includes magnesium in the chemical composition of a titanium oxide film, and thus, induces rapid and strong biochemical binding between the implant and bone tissue.
- Mg 2+ ions migrate to the outermost layer of the implant or migrate into bodily fluids so as to cause an ion exchange reaction with Ca 2+ ions present in the bodily fluids, thus resulting in migration of ions.
- the implant surface is electrostatically bound to bone matrix proteins having polyanionic properties, such as collagen type 1, thrombospondins, fibronectin, vitronectin, fibrillin, osteoadherin, osteopontin, bone sialoprotein, osteocalcin, osteonectin and BAG-75.
- bone matrix proteins having polyanionic properties, such as collagen type 1, thrombospondins, fibronectin, vitronectin, fibrillin, osteoadherin, osteopontin, bone sialoprotein, osteocalcin, osteonectin and BAG-75.
- Such electrostatic binding between the implant and bone matrix proteins serially promotes biomineralization around the implant.
- the implant in accordance with the present invention has a porous magnesium titanate surface and in turn, induces ingrowth of bone tissue into surface pores, thereby inducing a strong mechanical binding between the implant and bone tissue.
- the porous magnesium titanate oxide film has osseoinductive surface properties and thus the resulting synergistic effects of biochemical and mechanical binding between the implant and bone tissue produces rapid and strong osseointegration.
- the process for preparing a magnesium titanate oxide film implant in accordance with the present invention comprises the steps of: irradiating UV light on an implant body in distilled water for more than 2 hours; dipping the UN light- irradiated implant body in an electrolyte solution containing magnesium; and coating a magnesium titanate oxide film on the dipped implant body by anodic oxidation. Specifically, details are provided on respective steps for the above- mentioned process.
- the implant body is first washed and rinsed with suitable agents such as alcohols to degrease and then UV light is irradiated on the implant body in distilled water, for more than 2 hours. Irradiation of UV light on the implant body in distilled water for more than 2 hours is a technique affecting implantation of metal ions in anodic oxidation constituting the present invention. Then, the implant body thus irradiated is dipped in a magnesium- containing solution.
- the solution constituting the present invention is able to form a magnesium-containing titanium oxide film (a magnesium titanate oxide film, Ti x Mg y O z ) by low voltage dielectric breakdown anodic oxidation in accordance with the present invention, in any single or mixed solution containing magnesium, such as magnesium acetate, magnesium phosphate, magnesium sulphate, magnesium iodate, magnesium gluconate, magnesium nitrate, magnesium hydroxide and magnesium chloride.
- the magnesium titanate oxide film in accordance with the present invention preferably maintains magnesium content in a range of 1 to 35%.
- a composition ratio of the above-mentioned compounds in the solution may vary.
- a magnesium titanate oxide film is formed on the surface of the implant by inducing microarc on the positive electrode surface thereof at a low voltage of about 60 to 500 V.
- the magnesium titanate oxide film in accordance with the present invention provides creative and exclusive chemical constitution, differing from a conventional oxide film implant.
- Figs 1 and 2 are electron micrographs of an osseoinductive magnesium titanate oxide film implant after anodic oxidation in accordance with the present invention, respectively.
- Fig. 1 is an electron micrograph of the surface of an osseoinductive magnesium titanate oxide film, and
- Fig. 2 is a longitudinal cross-sectional view of the surface of the osseoinductive magnesium titanate oxide film implant.
- the surface of the magnesium titanate oxide film since the surface of the magnesium titanate oxide film has a porous magnesium titanate surface, it may induce ingrowth of bone tissue into those pores, thereby resulting in a strong mechanical binding between the implant and bone tissue.
- the osseoinductive magnesium titanate oxide film implant in accordance with the present invention comprise of an implant body 1 made up of titanium or a titanium alloy and magnesium titanate oxide films 2 and 3, the magnesium titanate oxide film being further divided into the surface porous oxide layer 3 and a barrier oxide layer 2 formed between the surface and implant body.
- the oxide film should have excellent mechanical properties (for example, compressive strength and tensile strength).
- the present invention increases current density up to 4,000 mA/cm 2 , when performing anodic oxidation. Increasing current density increases the growth rate of the barrier oxide layer on the implant surface, and the thickness of the lower barrier oxide layer 2 becomes relatively thicker, as compared to that of the surface porous oxide layer 3.
- the magnesium titanate oxide film in accordance with the present invention has structural characteristics which are more highly resistant to external forces, as compared to the conventional oxide film implant in which the entire oxide film is filled with pores or channels.
- the temperature of the solution is kept within 30°C as much as possible. Meanwhile, the thicker the oxide film is, the lower the mechanical strength such as tensile strength and compressive strength of the oxide film is, and thus, the titanate oxide film may be delaminated into bone tissue from the interface between the implant and bone tissue.
- the present invention provides optimized magnesium titanate oxide (Ti x Mg y O x ) thickness to effect successful osseointegration of the magnesium titanate oxide film implant. In order to accomplish this, at the same time, the present invention provides voltage (ranging from 60 to 500 V) producing the corresponding optimized thickness formation of the oxide film.
- agitation rate of a stirrer is maintained at more than 500 rpm to minimize gas adsorption on the positive electrode surface of the implant.
- Osseoinductive surface properties such as magnesium content and surface processibility, shape of the surface, and thickness of the oxide film in the magnesium titanate oxide film may vary depending on various factors such as the composition ratio of the solution, applied voltage, current density, solution temperature, agitation rate and pH. Except for these properties, the magnesium titanate oxide film in accordance with the present invention can be formed by using any conventional anodic oxidation methods and apparatuses.
- the present invention provides an optimum thickness of the magnesium titanate oxide film (Ti x Mg y O z ) to effect best successful osseointegration of a magnesium titanate (Ti x Mg y O z ) implant.
- the porous magnesium titanate oxide film (Ti x Mg y O z ) in accordance with the present invention has creative and exclusive osseoinductive surface properties, differing from conventional oxide film implants.
- incorporation of magnesium into the chemical composition of the implant oxide film induces rapid osseointegration by biochemical binding with bone tissue (biochemical osseointegration).
- the porous surface structure of the oxide film induces attachment of bone matrix proteins and ingrowth of bone tissue into the pores, and thereby provides opportunities to reinforce mechanical osseointegration with the implant (mechanical osseointegration).
- the porous magnesium titanate oxide film implant induces rapid and strong osseointegration due to the resulting synergistic effects of biochemical binding and mechanical binding between the implant and bone tissue, and thereby improves, on a long-term basis, functionality and success rate of the titanium and titanium alloy implants, in areas such as dentistry, orthopedic surgery, otorhinolaryngology, maxillofacial surgery and plastic surgery, so as to induce rapid and strong bone binding, thereby leading to successful osseointegration.
- Fig. 1 is an electron micrograph of the surface of an osseoinductive magnesium titanate oxide film implant in accordance with the present invention
- Fig. 2 is a longitudinal cross-sectional view of the surface of an osseoinductive magnesium titanate oxide, film implant in accordance with the present invention
- Fig. 3 shows results of qualitative analysis of a magnesium titanate oxide film in accordance with the present invention, by XPS analysis
- Fig. 4 shows results of qualitative analysis of Mg, among constituents of a magnesium titanate oxide film in accordance with the present invention, by XPS analysis
- Fig. 1 is an electron micrograph of the surface of an osseoinductive magnesium titanate oxide film implant in accordance with the present invention
- Fig. 2 is a longitudinal cross-sectional view of the surface of an osseoinductive magnesium titanate oxide, film implant in accordance with the present invention
- Fig. 3 shows results of qualitative analysis of a magnesium titanate oxide film in accordance with the present invention, by XPS analysis
- Fig. 4 shows
- Fig. 5 shows results of a qualitative analysis of Ti, among constituents of a magnesium titanate oxide film in accordance with the present invention, by XPS analysis
- Fig. 6 shows results of qualitative analysis of O, among constituents of a magnesium titanate oxide film in accordance with the present invention, by XPS analysis
- Figs. 7 and 8 are, respectively, electron micrographs of the surface of a magnesium titanate oxide film in accordance with the present invention
- Fig. 9 is a graph showing a relationship between an increasing rate of a magnesium titanate oxide film in accordance with the present invention and time/voltage
- Fig. 10 is a graph showing a relationship between a thickness of a magnesium titanate oxide film in accordance with the present invention and voltage.
- Electron Microscopes SEM
- Transmission Electron Microscopes TEM
- XRD X-ray Diffraction
- the present invention performs qualitative or quantitative characterization of osseoinductive surface properties of magnesium titanate of the above-mentioned titanium/titanium alloy implant, such as a chemical composition of magnesium titanate (Ti x Mg y O z ), a thickness of magnesium titanate, pore configurations thereof, shape and structure of surface and longitudinal cross-section of magnesium titanate and crystallinity thereof.
- Specific experimental conditions are presented in the following Examples. These examples are provided only for illustrating the present invention and should not be construed as limiting the scope and sprit of the present invention.
- EXAMPLES in accordance with Examples of the present invention, as an electrolyte solution for forming a magnesium titanate oxide film, 0.01 M to 1.0 M magnesium acetate, magnesium phosphate, magnesium sulphate, magnesium iodate, magnesium gluconate, magnesium nitrate, magnesium hydroxide, magnesium chloride or ethylenediamine tetraacetic acid was used alone or in any mixed solution thereof. Further, in order to adjust pH of a single or mixed solution to a range between 3.0 and 12.5, sulfuric acid, phosphoric acid, or various organic acids, for example, acetic acid, oxalic acid, malic acid, succinic acid, malonic acid, or boric acid was further added.
- a buffering agent such as sodium hydroxide or potassium hydroxide was added. Where such buffering agent was added, the total concentration of the electrolyte solution increased up to 20 M.
- current density of the electrolyte solution containing magnesium was set to a range of between 10 and 4000 mA.
- voltage for performing anodic oxidation was variously set within a range of between DC 23 to 500 V.
- agitation rate was maintained above 500 rpm and the solution temperature was kept below 30°C.
- Table 2 shows quantitative indication of XPS analysis on atomic composition of a magnesium titanate oxide film formed on the implant surface by low voltage dielectric breakdown anodic oxidation in a magnesium-containing solution in accordance with Examples, of the present invention.
- magnesium titanate in accordance with the present invention contains 6 to 26% of titanium, 51 to 71% of oxygen and 1.8 to 32% of magnesium, as main ingredients, 6 to 15%) of carbon, 0.3 to 6% of phosphorus, 0.3 to 2.1%o of sodium and 1 to 2% of nitrogen, as minor ingredients, and sulfur, calcium and potassium in a small amount of less than 1%.
- Figs 3 through 6 show results of a qualitative analysis of a magnesium titanate oxide film in accordance with the present invention, by XPS analysis. As can be seen from Fig. 4, magnesium shows chemical shifting from 1303.96 eV up to 1302.88 eV in binding energy at Mg Is.
- Fig. 7 is an electron micrograph of a surface of a magnesium titanate oxide film in the case of a lower concentration of the electrolyte solution
- Fig. 8 is an electron micrograph of a surface of a magnesium titanate oxide film in the case of a higher concentration of the electrolyte solution.
- the magnesium titanate oxide film formed in the higher concentration mixed solution has greater surface porosity, as compared to the magnesium titanate oxide film formed in the lower concentration mixed solution.
- magnesium content in the magnesium titanate oxide film also varies depending on changes in current density.
- the thickness of the film increases.
- increased current density of up to 4000 mA/cm 2 contributes to an increased pore size on the surface of the magnesium titanate oxide film, and increased surface porosity induces attacliment of proteins and ingrowth of bone tissue into pores, thereby reinforcing mechanical binding with the implant.
- changes in voltage at which anodic oxidation on the magnesium titanate oxide film occurs provides the following results.
- the thickness of the magnesium titanate oxide film may increase up to several tens of micrometers proportional to a given voltage along with time.
- the thickness of the oxide film containing magnesium may grow up to 30 ⁇ m at a voltage of DC 500 V.
- Voltage for colloidal deposition of magnesium ions into the oxide film and simultaneously, formation of pores on the surface of the magnesium titanate oxide film is DC 60 V.
- dielectric breakdown voltage necessary for making the thickness of 300 nm to 20 ⁇ m, which is an optimum magnesium titanate oxide film thickness for successful osseointegration of the magnesium titanate oxide film implant is 60 to 450 V.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Metallurgy (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dentistry (AREA)
- Materials Engineering (AREA)
- Ceramic Engineering (AREA)
- Electrochemistry (AREA)
- Mechanical Engineering (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Materials For Medical Uses (AREA)
- Prostheses (AREA)
Abstract
The present invention relates to a magnesium titanate oxide film implant for insertion into a living body, utilized in medical fields such as dentistry, orthopedic surgery, maxillofacial surgery and plastic surgery, and a method for preparing the same. The magnesium titanate oxide film implant in accordance with the present invention is prepared by forming a titanium oxide film (a magnesium titanate oxide film) in which magnesium is incorporated into the surface of titanium or a titanium alloy. A process for preparing a magnesium titanate oxide film implant in accordance with the present invention comprises irradiating UV light on an implant body made of titanium or a titanium alloy in distilled water for more than 2 hours; dipping the UV light-irradiated implant body in an electrolyte solution containing magnesium; and coating a magnesium titanate oxide film on the dipped implant body by anodic oxidation at a voltage of 60 to 500 V. Therefore, the present invention can provide an implant having increased bioactivity of a titanium oxide film formed by anodic oxidation, and provides an optimum magnesium titanate oxide (TiXMgyOZ) thickness for successful osseointegration of the magnesium titanate (Tix,MgyOZ) implant.
Description
[DESCRIPTION] [Invention Title] OSSEOINDUCTIVE MAGNESIUM-TITANATE IMPLANT AND METHOD OF MANUFACTURING THE SAME
[Technical Field] The present invention relates to a magnesium titanate oxide film implant for insertion into a living body, utilized in medical fields such as dentistry, orthopedic surgery, maxillofacial surgery and plastic surgery, and a method for preparing the same.
[Background Art] Generally, titanium (or titanium alloy) implants are subjected to a variety of surface treatments to improve biocompatibility thereof following lathe processing and milling. As examples of such surface treatment methods, mention may be made of etching in acidic/alkaline solutions, particle blasting, plasma spray, thermal oxidation, sol-gel induced coating using bioactive materials such as hydroxyapatite, bioglass and bioceramics, physical/chemical vapor deposition, Ion Implantation or Plasma Source Ion Implantation, electrochemical anodic oxidation and applied techniques using any combination thereof. As examples of surface treatment methods using the electrochemical anodic oxidation among those methods, there are known a method for preparing an oxide film using a mixed solution of sulfuric acid and hydrochloric acid, or sulfuric acid and phosphoric acid, or phosphoric acid and oxalic acid (German Patent No. 2,216,432, Japanese Patent Publication Laid-Open No. Hei 02-194,195, Swedish
Patent No. 1999-01973), a method for preparing an oxide film containing calcium and phosphorus (US Patent No. 5,478,237), a method involving forming an anodized film, followed by heat treatment (US Patent No. 5,354,390), a method involving forming calcium-phosphate using anodic oxidation, followed by heat of hydration treatment so as to prepare hydroxyapatite (US Patent No. 5,354,390), a method for preparing dicalcium phosphate anhydrous (DCPA, CaHPO), tricalcium
phosphate (alpha-TCP), amorphous calcium phosphate (ACP) and dicalcium phosphate dihydrate (DCPD) (US Patent No. 5,997,62), using anodic oxidation, and a method for preparing a titanium oxide film by anodic oxidation (EP Patent Publication No. 0 676 179). However, implants in which titanium or titanium alloy was coated with the above-mentioned calcium-phosphate or hydroxyapatite, have suffered from delamination of coated materials, or biodegradation and resorption due to biological actions at interfaces between an implant body and coating materials or inside coating materials, thus causing chronic inflammation of bone tissue in the vicinity of the implant, and thereby prolonged use thereof may result in continuous drop of a success rate. Further, the thicker the oxide film is, the lower the mechanical strength of the oxide film is, and the oxide film may be delaminated into bone tissue from the interface between the implant and bone tissue. [Disclosure] [Technical Problem] Therefore, the present invention has been made in view of the above problems, and it is an object of the present invention to provide a magnesium titanate oxide film implant having increased biocompatibility and bioactivity of a titanium oxide film formed by anodic oxidation, and a process for preparing the same. It is another object of the present invention to provide a magnesium titanate oxide film implant, by forming an oxide film having osseoinductive properties and excellent mechanical strength on surfaces of titanium and titanium alloy implants, which are utilized in dentistry, orthopedic surgery, otorhinolaryngology, maxillofacial surgery and plastic surgery, so as to induce rapid and strong bone binding, thereby leading to successful osseointegration; and a method for preparing the same. [Technical Solution]
In accordance with an aspect of the present invention, the above and other objects can be accomplished by the provision of a magnesium titanate oxide film implant, comprising: an implant body containing titanium or a titanium alloy; and a magnesium titanate oxide film formed on the surface of the body.
In the present invention, the magnesium titanate oxide film is prepared by low voltage dielectric breakdown anodic oxidation. Preferably, the magnesium titanate oxide film contains 6 to 26% of titanium, 51 to 71% of oxygen and 1.8 to 32%) of magnesium, as main ingredients; 6 to 15% of carbon, 0.3 to 6% of phosphorus, 0.3 to 2.1% of sodium and 1 to 2% of nitrogen, as minor ingredients; and, sulfur, calcium and potassium in an amount of less than 1%, as additives. In accordance with another aspect of the present invention, there is provided a process for preparing a magnesium titanate oxide film implant, comprising: irradiating UN light on an implant body made of titanium or a titanium alloy in distilled water for more than 2 hours; dipping the UN light-irradiated implant body in an electrolyte solution containing magnesium; and coating a magnesium titanate oxide film on the dipped implant body by anodic oxidation at a voltage of 60 to 500N.
Now, a magnesium titanate oxide film implant in accordance with the present invention and a process for preparing the same will be described in detail with reference to the accompanying drawings. The magnesium titanate oxide film implant in accordance with the present invention is composed of an implant body and a magnesium titanate oxide film formed on the surface of the implant body. The implant body used in the present invention is made of titanium or a titanium alloy. The magnesium titanate oxide film is formed by incorporating magnesium into the oxide film of the implant at low voltage by dielectric breakdown anodic oxidation, and preferably, contains 1.8 to
50% of magnesium, 6 to 26% of titanium and 51 to 71% of oxygen in an atomic ratio, as main ingredients, and optionally, may further contain 6 to 15% of carbon, 0.3 to 6% of phosphorus, 0.3 to 2.1% of sodium, 1 to 2% of nitrogen, and trace amounts of sulfur, calcium and potassium. Additionally, the magnesium titanate oxide film has a bilayer structure including an upper porous layer and a lower barrier oxide layer. The magnesium titanate oxide film preferably has a thickness of 300 nm to 30 μm, and more preferably 500 nm to 10 μm. The biochemical action mechanism of the magnesium titanate oxide film implant having such a constitution is as follows. The magnesium titanate oxide film implant further includes magnesium in the chemical composition of a titanium oxide film, and thus, induces rapid and strong biochemical binding between the implant and bone tissue. Mg2+ ions migrate to the outermost layer of the implant or migrate into bodily fluids so as to cause an ion exchange reaction with Ca2+ ions present in the bodily fluids, thus resulting in migration of ions. As a result, the implant surface is electrostatically bound to bone matrix proteins having polyanionic properties, such as collagen type 1, thrombospondins, fibronectin, vitronectin, fibrillin, osteoadherin, osteopontin, bone sialoprotein, osteocalcin, osteonectin and BAG-75. Such electrostatic binding between the implant and bone matrix proteins serially promotes biomineralization around the implant. Further, the implant in accordance with the present invention has a porous magnesium titanate surface and in turn, induces ingrowth of bone tissue into surface pores, thereby inducing a strong mechanical binding between the implant and bone tissue. That is, the porous magnesium titanate oxide film has osseoinductive surface properties and thus the resulting synergistic effects of biochemical and mechanical binding between the implant and bone tissue produces rapid and strong osseointegration. Next, a process for preparing a magnesium titanate oxide film implant in accordance with the present invention will be described. The process for preparing a magnesium titanate oxide film implant in accordance with the present invention comprises the steps of: irradiating UV light on an implant body in distilled water for more than 2 hours; dipping the UN light- irradiated implant body in an electrolyte solution containing magnesium; and
coating a magnesium titanate oxide film on the dipped implant body by anodic oxidation. Specifically, details are provided on respective steps for the above- mentioned process. The implant body is first washed and rinsed with suitable agents such as alcohols to degrease and then UV light is irradiated on the implant body in distilled water, for more than 2 hours. Irradiation of UV light on the implant body in distilled water for more than 2 hours is a technique affecting implantation of metal ions in anodic oxidation constituting the present invention. Then, the implant body thus irradiated is dipped in a magnesium- containing solution. The solution constituting the present invention is able to form a magnesium-containing titanium oxide film (a magnesium titanate oxide film, TixMgyOz) by low voltage dielectric breakdown anodic oxidation in accordance with the present invention, in any single or mixed solution containing magnesium, such as magnesium acetate, magnesium phosphate, magnesium sulphate, magnesium iodate, magnesium gluconate, magnesium nitrate, magnesium hydroxide and magnesium chloride. In addition, the magnesium titanate oxide film in accordance with the present invention preferably maintains magnesium content in a range of 1 to 35%. For this purpose, a composition ratio of the above-mentioned compounds in the solution may vary. Further, in order to adjust a pH of any single or mixed solution containing magnesium, there may be added sulfuric acid, phosphoric acid, various organic acids, for example, acetic acid, oxalic acid, malic acid, succinic acid, malonic acid, and boric acid, sodium hydroxide or potassium hydroxide as a buffering agent. Next, using the implant as the positive electrode and platinum as the negative electrode, a magnesium titanate oxide film is formed on the surface of the implant by inducing microarc on the positive electrode surface thereof at a low voltage of about 60 to 500 V. Although a mechanism of forming the magnesium titanate oxide film is not fully known, it is believed that magnesium ions or magnesium complex ion compounds undergo colloidal deposition by a driving force of electric field. The magnesium titanate oxide film in accordance with the present
invention provides creative and exclusive chemical constitution, differing from a conventional oxide film implant. Figs 1 and 2 are electron micrographs of an osseoinductive magnesium titanate oxide film implant after anodic oxidation in accordance with the present invention, respectively. Fig. 1 is an electron micrograph of the surface of an osseoinductive magnesium titanate oxide film, and
Fig. 2 is a longitudinal cross-sectional view of the surface of the osseoinductive magnesium titanate oxide film implant. As shown in Fig. 1, since the surface of the magnesium titanate oxide film has a porous magnesium titanate surface, it may induce ingrowth of bone tissue into those pores, thereby resulting in a strong mechanical binding between the implant and bone tissue. As shown in Fig. 2, the osseoinductive magnesium titanate oxide film implant in accordance with the present invention comprise of an implant body 1 made up of titanium or a titanium alloy and magnesium titanate oxide films 2 and 3, the magnesium titanate oxide film being further divided into the surface porous oxide layer 3 and a barrier oxide layer 2 formed between the surface and implant body. In addition, in order to ensure prolonged and successful function of the implant in vivo, the oxide film should have excellent mechanical properties (for example, compressive strength and tensile strength). In order to structurally reinforce mechanical properties of the titanium oxide film containing magnesium, the present invention increases current density up to 4,000 mA/cm2, when performing anodic oxidation. Increasing current density increases the growth rate of the barrier oxide layer on the implant surface, and the thickness of the lower barrier oxide layer 2 becomes relatively thicker, as compared to that of the surface porous oxide layer 3. As a result, the magnesium titanate oxide film in accordance with the present invention has structural characteristics which are more highly resistant to external forces, as compared to the conventional oxide film implant in which the entire oxide film is filled with pores or channels. Further, as another method of increasing the growth rate of the titanium oxide film containing magnesium, the temperature of the solution is kept within 30°C as much as possible. Meanwhile, the thicker the oxide film is, the lower the mechanical strength
such as tensile strength and compressive strength of the oxide film is, and thus, the titanate oxide film may be delaminated into bone tissue from the interface between the implant and bone tissue. The present invention provides optimized magnesium titanate oxide (TixMgyOx) thickness to effect successful osseointegration of the magnesium titanate oxide film implant. In order to accomplish this, at the same time, the present invention provides voltage (ranging from 60 to 500 V) producing the corresponding optimized thickness formation of the oxide film. Additionally, in order to prevent weakening of mechanical strength of the magnesium titanate oxide film due to chemical and structural defects thereof resulting from capture of gas (largely, O , H2), which is produced in the course of a low voltage dielectric breakdown anodic oxidation process, on the positive electrode surface of the implant, agitation rate of a stirrer is maintained at more than 500 rpm to minimize gas adsorption on the positive electrode surface of the implant. Osseoinductive surface properties such as magnesium content and surface processibility, shape of the surface, and thickness of the oxide film in the magnesium titanate oxide film may vary depending on various factors such as the composition ratio of the solution, applied voltage, current density, solution temperature, agitation rate and pH. Except for these properties, the magnesium titanate oxide film in accordance with the present invention can be formed by using any conventional anodic oxidation methods and apparatuses.
[Advantageous Effects] The present invention provides an optimum thickness of the magnesium titanate oxide film (TixMgyOz) to effect best successful osseointegration of a magnesium titanate (TixMgyOz) implant. The porous magnesium titanate oxide film (TixMgyOz) in accordance with the present invention has creative and exclusive osseoinductive surface properties, differing from conventional oxide film implants. In particular, incorporation of magnesium into the chemical composition of the implant oxide film induces rapid osseointegration by biochemical binding with bone tissue (biochemical osseointegration). Also, the porous surface structure of the oxide film induces attachment of bone matrix
proteins and ingrowth of bone tissue into the pores, and thereby provides opportunities to reinforce mechanical osseointegration with the implant (mechanical osseointegration). As a result, the porous magnesium titanate oxide film implant induces rapid and strong osseointegration due to the resulting synergistic effects of biochemical binding and mechanical binding between the implant and bone tissue, and thereby improves, on a long-term basis, functionality and success rate of the titanium and titanium alloy implants, in areas such as dentistry, orthopedic surgery, otorhinolaryngology, maxillofacial surgery and plastic surgery, so as to induce rapid and strong bone binding, thereby leading to successful osseointegration.
[Description of Drawings] The above and other objects, features and other advantages of the present invention will be more clearly understood from the following detailed description taken in conjunction with the accompanying drawings, in which: Fig. 1 is an electron micrograph of the surface of an osseoinductive magnesium titanate oxide film implant in accordance with the present invention; Fig. 2 is a longitudinal cross-sectional view of the surface of an osseoinductive magnesium titanate oxide, film implant in accordance with the present invention; Fig. 3 shows results of qualitative analysis of a magnesium titanate oxide film in accordance with the present invention, by XPS analysis; Fig. 4 shows results of qualitative analysis of Mg, among constituents of a magnesium titanate oxide film in accordance with the present invention, by XPS analysis; Fig. 5 shows results of a qualitative analysis of Ti, among constituents of a magnesium titanate oxide film in accordance with the present invention, by XPS analysis; Fig. 6 shows results of qualitative analysis of O, among constituents of a magnesium titanate oxide film in accordance with the present invention, by XPS analysis;
Figs. 7 and 8 are, respectively, electron micrographs of the surface of a magnesium titanate oxide film in accordance with the present invention; Fig. 9 is a graph showing a relationship between an increasing rate of a magnesium titanate oxide film in accordance with the present invention and time/voltage; and Fig. 10 is a graph showing a relationship between a thickness of a magnesium titanate oxide film in accordance with the present invention and voltage. [Best Mode] Now, preferred embodiments of a magnesium titanate oxide film implant in accordance with the present invention and a process for preparing the same will be described in detail. Using high resolution surface analysis instruments such as X-ray Photoelectron Spectroscopes(XPS), Auger Electron Spectroscopes (AES), Scanning
Electron Microscopes (SEM), Transmission Electron Microscopes (TEM) and X-ray Diffraction (XRD), the present invention performs qualitative or quantitative characterization of osseoinductive surface properties of magnesium titanate of the above-mentioned titanium/titanium alloy implant, such as a chemical composition of magnesium titanate (TixMgyOz), a thickness of magnesium titanate, pore configurations thereof, shape and structure of surface and longitudinal cross-section of magnesium titanate and crystallinity thereof. Specific experimental conditions are presented in the following Examples. These examples are provided only for illustrating the present invention and should not be construed as limiting the scope and sprit of the present invention.
[Mode for Invention]
EXAMPLES In accordance with Examples of the present invention, as an electrolyte solution for forming a magnesium titanate oxide film, 0.01 M to 1.0 M magnesium
acetate, magnesium phosphate, magnesium sulphate, magnesium iodate, magnesium gluconate, magnesium nitrate, magnesium hydroxide, magnesium chloride or ethylenediamine tetraacetic acid was used alone or in any mixed solution thereof. Further, in order to adjust pH of a single or mixed solution to a range between 3.0 and 12.5, sulfuric acid, phosphoric acid, or various organic acids, for example, acetic acid, oxalic acid, malic acid, succinic acid, malonic acid, or boric acid was further added. In addition, a buffering agent such as sodium hydroxide or potassium hydroxide was added. Where such buffering agent was added, the total concentration of the electrolyte solution increased up to 20 M. In accordance with Examples of the present invention, current density of the electrolyte solution containing magnesium was set to a range of between 10 and 4000 mA. Additionally, in accordance with Examples of the present invention, voltage for performing anodic oxidation was variously set within a range of between DC 23 to 500 V. Further, in order to prevent chemical and/or structural weakening of mechanical strength of the magnesium titanate oxide film in accordance with Examples of the present invention, agitation rate was maintained above 500 rpm and the solution temperature was kept below 30°C. Briefly, experimental conditions for the above-mentioned examples are shown in Table 1 below.
Table 1
Table 2 shows quantitative indication of XPS analysis on atomic composition of a magnesium titanate oxide film formed on the implant surface by low voltage dielectric breakdown anodic oxidation in a magnesium-containing solution in accordance with Examples, of the present invention.
Table 2
As can be seen from Table 2 above, magnesium titanate in accordance with the present invention contains 6 to 26% of titanium, 51 to 71% of oxygen and 1.8 to 32% of magnesium, as main ingredients, 6 to 15%) of carbon, 0.3 to 6% of phosphorus, 0.3 to 2.1%o of sodium and 1 to 2% of nitrogen, as minor ingredients, and sulfur, calcium and potassium in a small amount of less than 1%. Figs 3 through 6 show results of a qualitative analysis of a magnesium titanate oxide film in accordance with the present invention, by XPS analysis. As can be seen from Fig. 4, magnesium shows chemical shifting from 1303.96 eV up to 1302.88 eV in binding energy at Mg Is. This means that the chemical binding state of the surface of the magnesium titanate oxide film varies depending upon elemental Mg content. Such results indicate that values of natural numbers x, y and z in the magnesium titanate oxide film may vary within a constant range. Next, varying the concentration of the electrolyte solution in the magnesium titanate oxide film imparts the following effects. Generally, in a curve showing voltage-to-time characteristics, higher concentrations of the electrolyte solution containing magnesium drop the formation rate of the magnesium titanate oxide film, and lowers dielectric breakdown voltage. Therefore, the higher the concentration of electrolyte solution containing magnesium became, the higher the amount of magnesium adsorbed into the titanium oxide film became, until the magnesium content reaches 32%. Fig. 7 is an electron micrograph of a surface of a magnesium titanate oxide film in the case of a lower concentration of the electrolyte solution, while Fig. 8 is an electron micrograph of a surface of a magnesium titanate oxide film in the case of a higher concentration of the electrolyte solution. As can be seen from Figs. 7 and 8, the magnesium titanate oxide film formed in the higher concentration mixed solution
has greater surface porosity, as compared to the magnesium titanate oxide film formed in the lower concentration mixed solution. In accordance with Examples of the present invention, magnesium content in the magnesium titanate oxide film also varies depending on changes in current density. In general, when the current density increases up to 4000 mA/cm2, a formation rate of the anodized film sharply increases, and as a result, the thickness of the film also increases. Further, increased current density of up to 4000 mA/cm2 contributes to an increased pore size on the surface of the magnesium titanate oxide film, and increased surface porosity induces attacliment of proteins and ingrowth of bone tissue into pores, thereby reinforcing mechanical binding with the implant. Next, changes in voltage at which anodic oxidation on the magnesium titanate oxide film occurs provides the following results. The thickness of the magnesium titanate oxide film may increase up to several tens of micrometers proportional to a given voltage along with time. For example, in any solution given in Table 1, the thickness of the oxide film containing magnesium may grow up to 30 μm at a voltage of DC 500 V. Voltage for colloidal deposition of magnesium ions into the oxide film and simultaneously, formation of pores on the surface of the magnesium titanate oxide film is DC 60 V. Further, since the thicker oxide film leads to lower mechanical strength thereof (for example, tensile strength, compressive strength), there is a great risk of delamination of the oxide film into bone tissue from the interface between the implant and bone tissue. Therefore, dielectric breakdown voltage necessary for making the thickness of 300 nm to 20 μm, which is an optimum magnesium titanate oxide film thickness for successful osseointegration of the magnesium titanate oxide film implant, is 60 to 450 V. This is a preferred voltage range by which the generated pore size and porosity of the magnesium titanate surface exerts osseoinductive properties while meeting magnesium content of more than 5% in the magnesium titanate oxide film. Although the preferred embodiments of the present invention have been disclosed for illustrative purposes, those skilled in the art will appreciate that various modifications, additions and substitutions are possible, without departing from the scope and spirit of the invention as disclosed in the accompanying claims.
Claims
[CLAIMS] [Claim 1] A magnesium titanate implant, comprising: an implant body containing titanium or a titanium alloy; and a magnesium titanate oxide film formed on the surface of the body. [Claim 2] The magnesium titanate implant as set forth in claim 1, wherein the magnesium titanate oxide film is prepared in a single or mixed solution containing magnesium by low voltage dielectric breakdown anodic oxidation. [Claim 3]
The magnesium titanate implant as set forth in claim 1 or 2, wherein the magnesium titanate oxide film contains 6 to 26% of titanium, 51 to 71% of oxygen and 1.8 to 32% of magnesium, as main ingredients. [Claim 4] The magnesium titanate implant as set forth in claim 1 or 2, wherein the magnesium titanate oxide film has a bilayer structure including an upper porous layer and a lower barrier layer. [Claim 5] The magnesium titanate implant as set forth in claim 1 or 2, wherein the magnesium titanate oxide film has a thickness of 300 nm to 30 μm. [Claim 6] The magnesium titanate implant as set forth in claim 5, wherein the magnesium titanate oxide film has a thickness of 500 nm to 10 μm. [Claim 7] A process for preparing a magnesium titanate oxide film implant, comprising: irradiating UV light on an implant body made of titanium or a titanium alloy in distilled water for more than 2 hours; dipping the UV light-irradiated implant body in an electrolyte solution containing magnesium; and coating a magnesium titanate oxide film on the dipped implant body by anodic oxidation at a voltage of 60 to 500V.
[Claim 8] The process as set forth in claim 7, wherein the electrolyte solution is a single or mixed solution containing magnesium. [Claim 9] The process as set forth in claim 7 or 8, wherein the electrolyte solution has a concentration ranging from 0.01M to 1.0M. [Claim 10] The process as set forth in claim 7 or 8, wherein the electrolyte solution has a pH of 3.0 to 12.5. [Claim 11 ]
The process as set forth in claim 7 or 8, wherein the current density for performing the anodic oxidation is within the range of 30 to 4000 mA/cm2.
Priority Applications (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/562,925 US7452566B2 (en) | 2004-03-04 | 2004-03-04 | Osseoinductive magnesium-titanate implant and method of manufacturing the same |
| EP20040717311 EP1659978B1 (en) | 2004-03-04 | 2004-03-04 | Osseoinductive magnesium-titanate implant and method of manufacturing the same |
| AT04717311T ATE482667T1 (en) | 2004-03-04 | 2004-03-04 | OSSEOINDUCTIVE MAGNESIUM-TITANIUM IMPLANT AND PRODUCTION METHOD THEREOF |
| BRPI0411404 BRPI0411404A (en) | 2004-03-04 | 2004-03-04 | osseoinductive magnesium titanate implant and manufacturing process |
| DE200460029377 DE602004029377D1 (en) | 2004-03-04 | 2004-03-04 | OSSEOINDUCTIVE MAGNESIUM TITANIUM IMPLANT AND METHOD OF MANUFACTURING THEREOF |
| PCT/KR2004/000460 WO2005084577A1 (en) | 2004-03-04 | 2004-03-04 | Osseoinductive magnesium-titanate implant and method of manufacturing the same |
| CN200480020967A CN100584289C (en) | 2004-03-04 | 2004-03-04 | Osseoinductive magnesium-titanate implant and method of manufacturing the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/KR2004/000460 WO2005084577A1 (en) | 2004-03-04 | 2004-03-04 | Osseoinductive magnesium-titanate implant and method of manufacturing the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2005084577A1 true WO2005084577A1 (en) | 2005-09-15 |
Family
ID=34918679
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/KR2004/000460 WO2005084577A1 (en) | 2004-03-04 | 2004-03-04 | Osseoinductive magnesium-titanate implant and method of manufacturing the same |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7452566B2 (en) |
| EP (1) | EP1659978B1 (en) |
| CN (1) | CN100584289C (en) |
| AT (1) | ATE482667T1 (en) |
| BR (1) | BRPI0411404A (en) |
| DE (1) | DE602004029377D1 (en) |
| WO (1) | WO2005084577A1 (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008056323A1 (en) * | 2006-11-10 | 2008-05-15 | Sandvik Intellectual Property Ab | Surgical implant composite materials and kits and methods of manufacture |
| WO2009147044A1 (en) * | 2008-06-03 | 2009-12-10 | Königsee Implantate und Instrumente zur Osteosynthese GmbH | Electrochemically produced, biologically degradation stable, ductile and adhesive titanium oxide surface layer applied to titanium or titanium based alloys |
| DE102008026558A1 (en) | 2008-06-03 | 2010-01-14 | Königsee Implantate und Instrumente zur Osteosynthese GmbH | Electrochemical immersion process in an aqueous electrolyte to produce a biologically degradable surface layer on bases of titanium or titanium-based alloys |
| US20120040102A1 (en) * | 2009-02-19 | 2012-02-16 | Neoss Limited | Surface Treatment Process for Implantable Medical Device |
| US8641778B2 (en) | 2008-01-22 | 2014-02-04 | The Alfred E. Mann Foundation For Scientific Research | Prosthesis attachment method and apparatus with soft tissue integrating seal |
| US9744263B2 (en) | 2007-07-09 | 2017-08-29 | Astra Tech Ab | Bone tissue implant comprising strontium ions |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0208642D0 (en) * | 2002-04-16 | 2002-05-22 | Accentus Plc | Metal implants |
| GB0405680D0 (en) * | 2004-03-13 | 2004-04-21 | Accentus Plc | Metal implants |
| KR20090017693A (en) * | 2006-06-12 | 2009-02-18 | 액센투스 피엘씨 | Metal implants |
| US20100136083A1 (en) * | 2007-01-15 | 2010-06-03 | Accentus Plc | Metal Implants |
| EP2022447A1 (en) * | 2007-07-09 | 2009-02-11 | Astra Tech AB | Nanosurface |
| JP5287861B2 (en) | 2007-10-03 | 2013-09-11 | アクセンタス メディカル リミテッド | Method for producing metal with biocidal properties |
| WO2011157758A1 (en) * | 2010-06-15 | 2011-12-22 | Innotere Gmbh | Bone implant comprising a magnesium-containing metallic material with reduced corrosion rate, and methods and kit for producing the bone implant |
| US8727203B2 (en) | 2010-09-16 | 2014-05-20 | Howmedica Osteonics Corp. | Methods for manufacturing porous orthopaedic implants |
| TW201215376A (en) * | 2010-10-07 | 2012-04-16 | Chang Gung Medical Technology Co Ltd | Method for surface treatment of dental implant |
| KR101419779B1 (en) * | 2012-04-09 | 2014-07-17 | 박기덕 | Method of manufacturing bone graft materials and bone graft materials thereby |
| US9949837B2 (en) | 2013-03-07 | 2018-04-24 | Howmedica Osteonics Corp. | Partially porous bone implant keel |
| KR101326609B1 (en) * | 2013-06-07 | 2013-11-20 | (주)코리아덴탈솔루션 | Automated for teeth processing machine for bone graft material |
| DE102013215835A1 (en) * | 2013-08-09 | 2015-02-12 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Process for the deposition of color markers from titanium oxides on medical products, coating system for the production of coated materials |
| CN103536371B (en) * | 2013-10-21 | 2016-03-23 | 中国科学院上海硅酸盐研究所 | A kind of dentistry implant and preparation method thereof |
| JP2015229792A (en) * | 2014-06-05 | 2015-12-21 | オリンパス株式会社 | Implant and production method thereof |
| CZ308151B6 (en) * | 2015-02-20 | 2020-01-22 | Lasak S.R.O. | Intra-bone implant with bioactive surface treatment and how to prepare it |
| CN104928678B (en) * | 2015-05-15 | 2019-06-14 | 佳木斯大学 | A kind of method that titaniferous surface of test piece prepares micro-nano structure magnesium titanate active function coating |
| US20200208291A1 (en) * | 2017-04-07 | 2020-07-02 | The Board Of Trustees Of The University Of Illinois | Nanostructured magnesium materials, methods and devices |
| WO2021030882A1 (en) * | 2019-08-16 | 2021-02-25 | Dos Santos Pavei Bruno | Improvement applied to dental implant |
| CN112168431A (en) * | 2020-10-23 | 2021-01-05 | 中国人民解放军空军军医大学 | Functional bionic porous titanium alloy femoral head support rod and preparation method thereof |
| CN112545713A (en) * | 2020-11-23 | 2021-03-26 | 天衍医疗器材有限公司 | Bone filling prosthesis and preparation process thereof |
| CN115969551A (en) * | 2023-02-20 | 2023-04-18 | 北京华益圣亚医疗器械有限公司 | Oral implant and manufacturing method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5383935A (en) * | 1992-07-22 | 1995-01-24 | Shirkhanzadeh; Morteza | Prosthetic implant with self-generated current for early fixation in skeletal bone |
| EP0676179B1 (en) * | 1994-03-10 | 2000-05-03 | Friadent GmbH | Dental implant |
| JP2003268481A (en) * | 2002-03-13 | 2003-09-25 | National Institute Of Advanced Industrial & Technology | Titanium composite material and implant using the same |
| KR20040046248A (en) * | 2002-11-26 | 2004-06-05 | 설영택 | Osseoinductive magnesium-titanate implant and method of manufacturing the same |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2135004A1 (en) * | 1971-07-14 | 1973-01-25 | Bosch Gmbh Robert | Dielectric oxide layer of non-electrolyte condenser - - formed by anodic oxidation combined with uv irradiation |
| SE514323C2 (en) * | 1999-05-31 | 2001-02-12 | Nobel Biocare Ab | Implants and procedure and use in implants |
-
2004
- 2004-03-04 AT AT04717311T patent/ATE482667T1/en not_active IP Right Cessation
- 2004-03-04 WO PCT/KR2004/000460 patent/WO2005084577A1/en not_active Application Discontinuation
- 2004-03-04 BR BRPI0411404 patent/BRPI0411404A/en not_active IP Right Cessation
- 2004-03-04 CN CN200480020967A patent/CN100584289C/en not_active Expired - Fee Related
- 2004-03-04 US US10/562,925 patent/US7452566B2/en not_active Expired - Fee Related
- 2004-03-04 EP EP20040717311 patent/EP1659978B1/en not_active Expired - Lifetime
- 2004-03-04 DE DE200460029377 patent/DE602004029377D1/en not_active Expired - Lifetime
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5383935A (en) * | 1992-07-22 | 1995-01-24 | Shirkhanzadeh; Morteza | Prosthetic implant with self-generated current for early fixation in skeletal bone |
| EP0676179B1 (en) * | 1994-03-10 | 2000-05-03 | Friadent GmbH | Dental implant |
| JP2003268481A (en) * | 2002-03-13 | 2003-09-25 | National Institute Of Advanced Industrial & Technology | Titanium composite material and implant using the same |
| KR20040046248A (en) * | 2002-11-26 | 2004-06-05 | 설영택 | Osseoinductive magnesium-titanate implant and method of manufacturing the same |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008056323A1 (en) * | 2006-11-10 | 2008-05-15 | Sandvik Intellectual Property Ab | Surgical implant composite materials and kits and methods of manufacture |
| US9744263B2 (en) | 2007-07-09 | 2017-08-29 | Astra Tech Ab | Bone tissue implant comprising strontium ions |
| US9889227B2 (en) | 2007-07-09 | 2018-02-13 | Astra Tech Ab | Bone tissue implant comprising strontium ions |
| US8641778B2 (en) | 2008-01-22 | 2014-02-04 | The Alfred E. Mann Foundation For Scientific Research | Prosthesis attachment method and apparatus with soft tissue integrating seal |
| WO2009147044A1 (en) * | 2008-06-03 | 2009-12-10 | Königsee Implantate und Instrumente zur Osteosynthese GmbH | Electrochemically produced, biologically degradation stable, ductile and adhesive titanium oxide surface layer applied to titanium or titanium based alloys |
| DE102008026557A1 (en) | 2008-06-03 | 2009-12-17 | Königsee Implantate und Instrumente zur Osteosynthese GmbH | Electrochemically produced, biodegradation-stable, ductile and adherent titanium oxide surface layer on titanium or titanium-based alloys |
| DE102008026558A1 (en) | 2008-06-03 | 2010-01-14 | Königsee Implantate und Instrumente zur Osteosynthese GmbH | Electrochemical immersion process in an aqueous electrolyte to produce a biologically degradable surface layer on bases of titanium or titanium-based alloys |
| US20120040102A1 (en) * | 2009-02-19 | 2012-02-16 | Neoss Limited | Surface Treatment Process for Implantable Medical Device |
| US10251975B2 (en) * | 2009-02-19 | 2019-04-09 | Neoss Limited | Surface treatment process for implantable medical device |
| EP2614842B1 (en) | 2009-02-19 | 2022-09-07 | Neoss Limited | Surface treatment process for implantable medical device |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1659978A4 (en) | 2009-02-25 |
| ATE482667T1 (en) | 2010-10-15 |
| CN100584289C (en) | 2010-01-27 |
| DE602004029377D1 (en) | 2010-11-11 |
| CN1826088A (en) | 2006-08-30 |
| EP1659978A1 (en) | 2006-05-31 |
| EP1659978B1 (en) | 2010-09-29 |
| BRPI0411404A (en) | 2006-07-25 |
| US7452566B2 (en) | 2008-11-18 |
| US20060161263A1 (en) | 2006-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7452566B2 (en) | Osseoinductive magnesium-titanate implant and method of manufacturing the same | |
| Wang et al. | Review of the biocompatibility of micro-arc oxidation coated titanium alloys | |
| Yao et al. | Synthesis and properties of hydroxyapatite-containing porous titania coating on ultrafine-grained titanium by micro-arc oxidation | |
| Chen et al. | Preparation and properties of hydroxyapatite-containing titania coating by micro-arc oxidation | |
| US8057657B2 (en) | Treatment of an osteointegrative interface | |
| Sul et al. | Optimum Surface Properties of Oxidized Implants for Reinforcement of Osseointeg ration: Surface Chemistry, Oxide Thickness, Porosity, Roughness, and Crystal Structure. | |
| US5478237A (en) | Implant and method of making the same | |
| US8382823B2 (en) | Biodegradable stent and method for manufacturing the same | |
| Wang et al. | The structure, bond strength and apatite-inducing ability of micro-arc oxidized tantalum and their response to annealing | |
| JP2005508862A (en) | Modified oxide | |
| KR100487119B1 (en) | Osseoinductive magnesium-titanate implant and method of manufacturing the same | |
| Masahashi et al. | Study of bioactivity on a TiNbSn alloy surface | |
| Zhu et al. | Characterization of hydrothermally treated anodic oxides containing Ca and P on titanium | |
| Yan et al. | The effect of chemical treatment on apatite-forming ability of the macroporous zirconia films formed by micro-arc oxidation | |
| Byon et al. | Apatite-forming ability of micro-arc plasma oxidized layer of titanium in simulated body fluids | |
| EP1515759B1 (en) | An osteointegrative interface for implantable prostheses and method for its manufacture | |
| Terleeva et al. | Microplasma synthesis of biocompatible coatings with additions of magnesium, silicon and silver on pure titanium from homogeneous electrolytes | |
| KR101311979B1 (en) | Method for preparing bio materials using coating of hydroxyapatite/zirconia composites and bio materials prepared therefrom | |
| Nguyen et al. | The effect of two-step surface modification for Ti-Ta-Mo-Zr alloys on bone regeneration: An evaluation using calvarial defect on rat model | |
| KR101081687B1 (en) | Method of fabricating bio-materials | |
| Cui et al. | Apatite formation on anodized Ti-6Al-4V alloy in simulated body fluid | |
| JP3129041B2 (en) | Implant and manufacturing method thereof | |
| JP3545505B2 (en) | Implant material and its manufacturing method | |
| JPH09308681A (en) | Metallic material having bone conductivity and its production | |
| Saleh et al. | Effect of UV rrradiation on apatite deposition on anodised TiO2 coating formed under mixed acid solution |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WWE | Wipo information: entry into national phase |
Ref document number: 200480020967.0 Country of ref document: CN |
|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 2004717311 Country of ref document: EP |
|
| ENP | Entry into the national phase |
Ref document number: 2006161263 Country of ref document: US Kind code of ref document: A1 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 10562925 Country of ref document: US |
|
| WWP | Wipo information: published in national office |
Ref document number: 2004717311 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 10562925 Country of ref document: US |
|
| ENP | Entry into the national phase |
Ref document number: PI0411404 Country of ref document: BR |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: DE |